Who
Elizabeth E. Reed
Chief Legal Officer and GC
Company insider
Files Form 4 as: Chief Legal Officer and GC, Travere Therapeutics; VP, General Counsel, Celladon; SVP, Legal Affairs and GC, Anadys Pharmaceuticals.
In numbers
- Trades disclosed
- 207
- Buys
- 0
- Sells
- 59
- Bought
- $0
- Sold
- $16.3M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 9 Jan 2006
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $580K37,500 at $15.46 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M21,926 at $62.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $869K13,874 at $62.63 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $89K1,400 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K300 at $65.31 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $580K37,500 at $15.46 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M21,926 at $62.03 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $869K13,874 at $62.63 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $89K1,400 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K300 at $65.31 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K2,076 at $43.95 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K2,076 at $43.95 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $101K2,174 at $46.65 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $101K2,174 at $46.65 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $359K20,000 at $17.96 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $900K20,000 at $45.00 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Elizabeth E. Reed; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.